AstraZeneca PLC (AZN)vsSotera Health Co (SHC)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
SHC
Sotera Health Co
$15.78
+0.70%
HEALTHCARE · Cap: $4.47B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4983% more annual revenue ($60.44B vs $1.19B). AZN leads profitability with a 17.2% profit margin vs 9.9%. AZN appears more attractively valued with a PEG of 1.52. SHC earns a higher WallStSmart Score of 68/100 (B-).
AZN
Buy62
out of 100
Grade: C+
SHC
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+2.9%
Fair Value
$17.89
Current Price
$15.78
$2.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Strong operational efficiency at 31.3%
Earnings expanding 175.4% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 4.14 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SHC is a value play — different risk/reward profiles.
SHC carries more volatility with a beta of 1.82 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SHC scores higher overall (68/100 vs 62/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?